Preclinical evaluation of itraconazole in docetaxel-resistant prostate cancer xenograft models
{{output}}
Docetaxel (DTX) resistance remains a major barrier in metastatic prostate cancer, often driven by ABCB1 efflux and activation of survival pathways. We investigated the therapeutic impact of itraconazole (ITZ), a multifunctional antifungal agent with activity a... ...
